Navigation Links
Antifolate in Medical News

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this phase ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this ...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Antifolate Drugs may Be Effective in Treating P Vivax Malaria

...Malaria and Leishmaniasis Control Programme in Pakistan, have revealed that antifolate drugs may be effective in treating P vivax malaria. Toby Leslie, M.Sc., and colleagues tested the relative efficacy and safety of two antifolate drugs (sulfadoxine-pyrimethamine and chlorproguanil-dapsone) against P viva...
Antifolate in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

... to focus solely on oncology assets. He led the licensing effort to acquire both oncology products currently in their portfolio: pralatrexate, a novel antifolate currently in a registration trial in peripheral T-cell lymphoma, and RH1, currently in a Phase 1 trial for solid tumors. Before Allos, Mr. Malek held ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... with chemotherapy. J Clin Oncol 2004; 22:1589-97. (3) Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66:431-...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

...ollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patie...ancer. The company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with rela...

Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting

...(tm) (talotrexin) for Injection Talvesta(tm) is a novel nonpolyglutamable antifolate drug under development for the treatment of various types of cancers. Talve...more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance. Talvesta also binds more tightly to its anti-tumor target DHFR,...
Antifolate in Biological Technology

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

...n vitro. PDX in NSCLC (Phase 1) The poster entitled "Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in ...ancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients ...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...
Other Tags
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... September 30, 2014 A group of Americans ... combat an epidemic that, left unchecked, could create a catastrophic, ... not headed to Africa. John Rogers, the Executive Director the ... Korea to fight a disease most think mankind conquered long ... 80 years ago is on the comeback in several countries ...
(Date:9/30/2014)... Clearwater, FL (PRWEB) September 30, 2014 ... (colon), declines with age, poor diet, and stress, so ... beneficial bacteria.* Each capsule of Ultimate Flora™ Men’s ... 58 billion cultures from 7 Bifidobacteria strains to support ... gas tends to build up, and 32 billion cultures ...
(Date:9/30/2014)... of Defense has made progress in reducing the stigma ... depression and post-traumatic stress disorder, but more improvement is ... , Despite efforts of both the Defense Department and ... many service members still do not seek needed care ... a concerted effort to promote treatment as a way ...
Breaking Medicine News(10 mins):Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3
(Date:9/30/2014)... Munich report that a new class of chemical ... drugs. They have also pinpointed the relevant target ... agents. , Researchers led by LMU,s Professor ... Technische Universitt Mnchen have identified a class of ... the fight against malignant tumors. The compound is ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
Other Contents